<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798159</url>
  </required_header>
  <id_info>
    <org_study_id>TD0025</org_study_id>
    <nct_id>NCT02798159</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TD0025 (Rocket1h) for Treatment of Erectile Dysfunction</brief_title>
  <acronym>TD0025</acronym>
  <official_title>A Randomized, Placebo Control, Double-blinded, Double-dummy, Phase 2/3 Combination Study to Evaluate the Safety and Efficacy of TD0025 (Rocket1h) Compared With Sildenafil Citrate for Treatment of Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vietstar Biomedical Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vietstar Biomedical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify the optimal dose(s) of TD0025 for treatment of
      erectile dysfunction (phase II) and to investigate if treatment of erectile dysfunction with
      the optimal dose of TD0025 taken as needed over one month is non-inferior than Sildenafil
      Citrate taken as needed over one month (phase III)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PART A- PHASE II: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), question # 3 and #4</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF) Erectile Function (EF) Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PART A- PHASE II: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Erectile Function (EF) Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART A- PHASE II: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Orgasmic Function Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART A- PHASE II: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Sexual Desire Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART A- PHASE II: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART A- PHASE II: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Overall Satisfaction Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART A- PHASE II: The percentage of patients with abnormal Testosterone, FSH, LH and Androgen Serum Levels at Baseline and after 4 weeks of treatment</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART A- PHASE II: The percentage of patients with abnormal hematology and biochemistry laboratory values at baseline and after 4 weeks of treatment</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Orgasmic Function Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Sexual Desire Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the International Index of Erectile Function (IIEF), Overall Satisfaction Domain</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Time to Discontinuation of Randomized Treatment</measure>
    <time_frame>Baseline up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the Sexual Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the Confidence Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the Self Esteem Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: Change From Baseline to 4 Weeks of the Overall Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: The percentage of patients with abnormal Testosterone, FSH, LH and Androgen Serum Levels at Baseline and after 4 weeks of treatment</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B- PHASE III: The percentage of patients with abnormal hematology and biochemistry laboratory values at baseline and after 4 weeks of treatment</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Part A- Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational dose = 0.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A- Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational dose = 0.5 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A- Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational dose = 1 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A- Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational dose = 1.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B- Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational dose = optimal dose in Part A. The drug should not be taken more than one time a day or 3 times a week.
Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B- Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil Citrate 50 mg on demand The drug should not be taken more than one time a day or 3 times a week. Administered orally once a day, 1 hour before sexual activity, for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD0025</intervention_name>
    <arm_group_label>Part A- Arm 1</arm_group_label>
    <arm_group_label>Part A- Arm 2</arm_group_label>
    <arm_group_label>Part A- Arm 3</arm_group_label>
    <arm_group_label>Part A- Arm 4</arm_group_label>
    <arm_group_label>Part B- Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate 50mg</intervention_name>
    <arm_group_label>Part B- Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  History of Erectile Dysfunction (ED) of at least 1 month duration.

          -  Anticipate having the same adult female sexual partner during the study.

          -  Agree not to use any other treatment for ED and to participate in recording responses
             to questionnaires and other instruments used in this study.

          -  Sign the informed consent form

        Main Exclusion Criteria:

          -  ED caused by other primary sexual disorders, history of radical prostatectomy or other
             pelvic surgery with subsequent failure to achieve any erection, or history of penile
             implant or clinically significant penile deformity

          -  ED caused by untreated or inadequately treated endocrine disease

          -  Current treatment with doxazocin, nitrates, cancer chemotherapy, or anti-androgens

          -  Severe renal or hepatic impairment, history of malignant hypertension

          -  Presence or history of specific heart conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nguyen Quang, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Men Sexual Health Centre, Vietnam- Germany Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nguyen T. Hong Van</last_name>
    <phone>04.3513583111</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Men Sexual Health Centre; Vietnam- Germany Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyen Quang, MD. PhD.</last_name>
      <phone>84. 4 3825 3531</phone>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sexual Dysfunction</keyword>
  <keyword>Physiological Sexual Dysfunctions</keyword>
  <keyword>Psychological Sexual and Gender Disorders</keyword>
  <keyword>Sildenafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

